Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities Scinai (NASDAQ: SCNI) completed a strategic reorganization on April 6, 2026, creating a dedicated CDMO subsidiary, Scinai Biopharma Services, following its February 2026 acquisition of Recipharm Israel (Yavne site). The move separates CDMO operations from a leaner R&D-focused Scinai Immunotherapeutics and targets ~$5 million in CDMO revenues for 2026.The CDMO platform combines Jerusalem biologics capabilities, Yavne small-molecule/API capacity, and a commercial collaboration with Recipharm that provides subcontracting access and referral-based royalties.

#SCNI Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

www.stocktitan.net/news/SCNI/scinai-complet...

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration Scinai (NASDAQ: SCNI) reported full-year 2025 results with CDMO revenues doubling to $1.3 million and a year-end cash position of $1.8 million. Net loss was $8.3 million, driven in part by the absence of 2024 financial income. Post‑year-end, Scinai acquired Recipharm Israel and signed a strategic collaboration to expand CDMO capabilities into small‑molecule manufacturing. The company resubmitted a FENG grant request that could provide up to €12 million in funding matched by ~€3 million company investment.

#SCNI Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

www.stocktitan.net/news/SCNI/scinai-reports...

After its Recipharm deal, Scinai takes expanded drug-making pitch to Europe Lisbon meetings run March 23-25 as Scinai seeks CDMO clients and immunology partners, its first major global event after the Recipharm Israel deal.

#SCNI Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

www.stocktitan.net/news/SCNI/scinai-immunot...

Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Scinai Immunotherapeutics (Nasdaq: SCNI) said it received a Nasdaq written notice dated March 12, 2026, for noncompliance with the Nasdaq Capital Market minimum $1.00 bid price rule after ADSs closed below $1.00 for 30 consecutive business days.The notice does not affect current listing or trading and provides an initial 180-calendar-day compliance period through September 8, 2026 to regain the $1.00 minimum by achieving at least ten consecutive business days at or above $1.00. The company said it will monitor the ADS closing price and evaluate options to regain compliance.

#SCNI Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

www.stocktitan.net/news/SCNI/scinai-immunot...

Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept Scinai (Nasdaq: SCNI) executed a Second Amendment to its PinCell option agreement and submitted a revised €12 million non-dilutive FENG SMART Path application to support a €15 million integrated R&D program for PC111, a fully human anti-sFasL antibody for PV and SJS/TEN.The amendment extends option condition deadlines to August 31, 2026 and the exercise period to September 30, 2026. A funding decision is expected in approximately three to four months.

#SCNI Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

www.stocktitan.net/news/SCNI/scinai-signs-s...

Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances Revenues for the nine months ended September 30, 2025 were $1,049 thousand, compared to $452 thousand for the nine months ended September 30, 2024. The increase reflects continued expansion of Scinai Bioservices, including contributions from the Company's U.S. subsidiary. R&D expenses for the nine months ended September 30, 2025 amounted to $1,799...

#SCNI Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances

www.stocktitan.net/news/SCNI/scinai-reports...

é aqui que começa a historia

[ #art #brart #SCNI]

Les savoir-faire écosourcés : interview de Frédéric Létoffé sur les SCNI Interview de Frédéric Létoffé, responsable du projet Recherche et Développement Métiers sur les savoir-faire écosourcés, au sujet des SCNI, les systèmes constructifs non industrialisés.

VIDÉO | Les savoir-faire écosourcés : interview de Frédéric Létoffé sur les SCNI batinfo.com/video/les-sa... #Interview #Recherche #Matériau #Développement #SCNI #Vidéo

Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities Scinai (NASDAQ: SCNI) received a non-dilutive Israel Innovation Authority grant of NIS 809,000 (~$246,000), funding ~66% of a NIS 1.23 million (~$373,000) project to acquire and install an advanced small-batch sterile fill-and-finish system.Installation and qualification are expected in Q1 2026 with commercial operation planned in Q2 2026. The upgrade aims to expand Scinai Bioservices' GMP fill-and-finish capacity, enable rapid batch turnaround across primary packaging formats, and support clients in Israel, the U.S., and Europe while meeting EMA and FDA cGMP standards.Scinai also continues R&D programs and holds an option to acquire PinCell Srl (PC111) and retains licensing options for NanoAbs from MPG and UMG.

#SCNI Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities

www.stocktitan.net/news/SCNI/scinai-awarded...

172% Revenue Surge: Scinai's CDMO Business Powers Growth as Biotech Secures $4.2M and Expands Pipeline Scinai's CDMO revenues hit $773K in H1 2025, up from $284K YoY. Company raised $4.2M post-period, advances IL-17 NanoAb programs, and pursues €15M EU grant for clinical trials.

#SCNI Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

www.stocktitan.net/news/SCNI/scinai-reports...

Just In: ( NASDAQ: #SCNI ) Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN Scinai Immunotherapeutics (NASDAQ:SCNI) announced a new peer-reviewed publication validating PC111, their first-in-class human anti-Fas Ligand monoclonal antibody, as a potential disease-modifying therapy for pemphigus and SJS/TEN. The research, published in the Journal of Dermatological Treatment, demonstrates PC111's ability to prevent blister formation across multiple study models.The study confirms PC111's unique non-immunosuppressive mechanism, acting locally at the keratinocyte level. The treatment represents a market opportunity exceeding $1 billion annually. Scinai and Pincell plan to advance PC111 through IND-enabling studies, with potential market entry in 3-4 years. The program may receive up to 80% cost coverage through a €15 million FENG grant, pending Q3 2025 decision.

#SCNI Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

www.stocktitan.net/news/SCNI/scinai-announc...

Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology" Scinai Immunotherapeutics (NASDAQ:SCNI) announces that Dr. Roberta Lotti from Pincell Srl has received the prestigious "Oscar of Italian Dermatology" for her groundbreaking research on PC111, a first-in-class anti-Fas Ligand monoclonal antibody. The award recognizes Dr. Lotti's paper demonstrating PC111's efficacy in treating pemphigus through a novel, non-immunosuppressive approach.PC111, which Scinai has rights to through a strategic option agreement to acquire Pincell srl, targets soluble Fas Ligand (sFasL) in Pemphigus Vulgaris (PV) and Stevens-Johnson/Toxic Epidermal Necrolysis (SJS/TEN). The research confirms that PC111 blocks blister formation by inhibiting keratinocyte apoptosis, representing a potential paradigm shift from current immunosuppressive treatments.

#SCNI Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"

www.stocktitan.net/news/SCNI/scinai-highlig...

Scinai CDMO Revenue Set to Double in 2025: Inside the Biotech's $12M Annual Revenue Potential Scinai secures fresh capital and projects CDMO revenue surge to $2M in 2025. Dual-revenue strategy combines contract manufacturing with therapeutic development. Learn more.

#SCNI Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

www.stocktitan.net/news/SCNI/scinai-highlig...

JUST IN: ( NASDAQ: #SCNI ) BioMedNewsBreaks - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Italian Clearance for Option to Acquire Biotech Firm Pincell

Major Breakthrough: Scinai Clears Critical Hurdle in €12M Rare Disease Drug Acquisition Deal Italian government approves Scinai's planned takeover of Pincell, advancing orphan drug development for severe skin conditions. €12M grant decision pending. Learn more.

#SCNI Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

www.stocktitan.net/news/SCNI/scinai-immunot...

Scinai Q1 Earnings Show CDMO Business Momentum Despite $1M Cash Position: Key Metrics Revealed Scinai's Q1 shows CDMO revenue acceleration and improved bottom line, while cash reserves require attention. See complete financial analysis and growth metrics.

#SCNI Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

www.stocktitan.net/news/SCNI/scinai-reports...

Scinai Announces Annual Financial Results for 2024 Scinai Immunotherapeutics (NASDAQ: SCNI) reported its 2024 annual financial results, marking significant changes in its financial position. The company generated its first-ever revenue of $658,000 through its CDMO business unit. R&D expenses slightly increased to $5.6 million from $5.2 million in 2023. Marketing and administrative expenses decreased to $2.6 million from $4.5 million. Notably, the company achieved a net gain of $4.8 million in 2024, compared to a $6.5 million loss in 2023, primarily due to $14.8 million in financial income from loan conversion to equity. However, cash position decreased to $1.9 million as of December 31, 2024, down from $4.9 million in 2023.

#SCNI Scinai Announces Annual Financial Results for 2024

www.stocktitan.net/news/SCNI/scinai-announc...

Major Rare Disease Breakthrough: Scinai Acquires Novel Antibody Treatment for Severe Skin Conditions Novel antibody PC111 targets multiple rare skin diseases with orphan drug designation. Strategic acquisition expands treatment pipeline for unmet medical needs.

#SCNI Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

www.stocktitan.net/news/SCNI/scinai-signs-a...

Scinai Reveals Game-Changing Immunotherapy Pipeline at Major European Biotech Conference Scinai leadership team presents innovative NanoAbs pipeline and premium CDMO services at BIO-Europe Spring 2025. Schedule one-on-one meetings with executives in Milan.

#SCNI Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

www.stocktitan.net/news/SCNI/scinai-to-conn...

How Will Scinai's New $10M Funding Agreement Strengthen Its Biotech Pipeline? Three-year agreement provides Scinai with discretionary capital access at minimal 3% discount without warrants or fundraising restrictions

#SCNI SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

www.stocktitan.net/news/SCNI/scinai-immunot...

Scinai Immunotherapeutics to Present at Major Healthcare Conferences Including JP Morgan 2025 Scinai's leadership team will showcase NanoAbs technology and CDMO services at three prestigious US healthcare conferences in January, meeting investors and potential partners.

#SCNI Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

www.stocktitan.net/news/SCNI/scinai-to-conn...

Scinai Immunotherapeutics Launches U.S. CDMO Division, Secures First American Client Amid Biotech Manufacturing Expansion Scinai expands CDMO services to U.S. market with new subsidiary, leveraging 20,000 sq ft FDA-compliant facility and growing biotech manufacturing portfolio of 9 clients.

#SCNI Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

www.stocktitan.net/news/SCNI/scinai-immunot...

BREAKING NEWS: ( NASDAQ: #SCNI ) InvestorNewsBreaks - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Welcomes Dr. Jonathan Sadeh to Scientific Advisory Board

#StockMarket #News

Breaking News: ( NASDAQ: #SCNI ) Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

#StockMarket #News

Thoughts on #SCNI 📊 #stocks #stockmarket #news

#SCNI Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

www.stocktitan.net/news/SCNI/dr-jonathan-sa...

Breaking News: ( NASDAQ: #SCNI ) InvestorNewsBreaks - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Nine-Month Financial Results and Business Update

#StockMarket #News

Just In: ( NASDAQ: #SCNI ) Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

#StockMarket #News